Herantis Pharma Announces Successful HER-096 Initial Results with Nanoform Technology

Herantis Pharma Plc

Press release 24 Mar 2022 at 09:00 am EET

Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced:

  • Results of proof-of-concept study demonstrating successful nanoforming of HER-096 into nanoparticles
  • Further exploration the applicability of Nanoform’s technology in the development of an oral dosage form based on HER-096 nanoparticles.

Herantis has previously shown that HER-096 penetrates the blood brain barrier (BBB) and enters the brain in therapeutic concentrations in healthy rats following subcutaneous administration. Subcutaneous administration will be used in Herantis’ HER-096 first-in-human clinical study that is expected to commence in 2023.

“Herantis remains focused on the development of HER-096 and will concentrate its efforts on getting it into clinic as soon as possible with the simple subcutaneous administration. Moreover, we are pleased to announce the collaboration with Nanoform to explore the feasibility of developing an oral dosage form of HER-096,” said Antti Vuolanto, COO of Herantis.

“We are excited that nanoforming has been successfully applied to Herantis' HER-096 compound as well as the CDNF protein. This proof-of-concept study further validates the wide applicability of Nanoform’s technologies to a diverse range of molecules. We look forward to further nanoforming activities as HER-096 continues its development” said Christian Jones, Chief Commercial Officer of Nanoform.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.

About Nanoform Finland Plc

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications.

Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). For more information, please visit  http://www.nanoform.com.